Information for the public
Ruxolitinib (Jakavi) is recommended as a possible treatment for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only:
if they have intermediate‑2 or high-risk disease.
If you have an enlarged spleen or symptoms caused by one of these types of myelofibrosis, and your doctor thinks that ruxolitinib is the right treatment, you should be able to have the treatment on the NHS.
Ruxolitinib should be available on the NHS within 3 months of the guidance being issued.
If you are not eligible for treatment you should be able to continue taking ruxolitinib until you and your doctor decide it is the right time to stop.